<DOC>
	<DOCNO>NCT02151526</DOCNO>
	<brief_summary>This Phase 1/2 , open label , safety , efficacy study administration LentiGlobin BB305 Drug Product subject either beta-thalassemia major severe sickle cell disease ( SCD ) .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Safety LentiGlobin BB305 Drug Product Beta-Thalassemia Major Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>1 . Be 5 35 year age , inclusive . 2 . Have severe sickle cell disease ( SCD ) transfusion dependent betathalassemia major , regardless genotype diagnosis confirm Hb study . Transfusion dependence define require least 100 mL/kg/year pack red blood cell ( pRBCs ) . 3 . Be eligible allogeneic HSC transplant base institutional medical guideline , without match related donor . 4 . Have treat follow least past 2 year specialize center maintain detailed medical record , include transfusion history . Subjects severe SCD also must : 5 . Have fail achieve adequate clinical benefit follow hydroxyurea treatment sufficient dosage , least 4 month unless treatment indicate well tolerate . 6 . Have 1 follow poor prognostic risk factor : Recurrent vaso occlusive crisis ( least 2 episode precede year year prior start regular transfusion program ) . Presence significant cerebral abnormality magnetic resonance imaging ( MRI ) ( stenosis occlusion ) . Stroke without severe cognitive disability . Osteonecrosis 2 joint . Antierythrocyte alloimmunization ( &gt; 2 antibody ) . Presence sickle cell cardiomyopathy document Doppler echocardiography . Acute chest syndrome ( least 2 episode ) define acute event pneumonialike symptom ( e.g. , cough , fever [ &gt; 38.5°C ] , acute dyspnea , expectoration , chest pain , finding upon lung auscultation , tachypnea , wheeze ) presence new pulmonary infiltrate . Subjects chronic oxygen saturation &lt; 90 % ( exclude period SCD crisis ) carbon monoxide diffuse capacity ( DLco ) less 60 % absence infection include study . 1 . Availability willing 10 /10 match HLA identical sibling hematopoietic cell donor , unless recommendation enrollment provide Comité de Surveillance follow review case . 2 . Clinically significant , active bacterial , viral , fungal , parasitic infection . 3 . Contraindication anesthesia bone marrow harvest . 4 . Any prior current malignancy , myeloproliferative immunodeficiency disorder . 5 . A white blood cell ( WBC ) count &lt; 3×10^9/L and/or platelet count &lt; 120×10^9/L . 6 . History major organ damage include : Liver disease , transaminase level &gt; 3× upper limit normal . This observation exclusionary liver biopsy show evidence extensive bridging fibrosis , cirrhosis , acute hepatitis . Histopathological evidence extensive bridging fibrosis , cirrhosis , acute hepatitis liver biopsy . Heart disease , leave ventricular ejection fraction &lt; 25 % . Kidney disease calculate creatinine clearance &lt; 30 % normal value . Severe iron overload , opinion physician ground exclusion . A cardiac T2* &lt; 10 m magnetic resonance imaging ( MRI ) . Evidence clinically significant pulmonary hypertension require medical intervention .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>